BACKGROUND: Altered sympathetic nervous system signaling is known to play a role in the cardiotoxicity of the anthracycline chemotherapeutic agents, but the interaction of pre- and postsynaptic function is not well understood. METHODS AND RESULTS: Our aim was to study the noradrenergic signaling in an established rat model of adriamycin cardiotoxicity (15 mg/kg administered i.p. over 2 weeks) using radiotracers having potential applicability for imaging with positron emission tomography (PET). Ex vivo biodistribution was performed 1 and 3 weeks post-adriamycin treatment with the noradrenaline analogue [(11)C]meta-hydroxyephedrine ([(11)C]HED), beta-adrenergic receptor antagonist [(3)H]CGP12177, and phosphodiesterase-4 inhibitor (R)-[(11)C]rolipram. Cardiac function (echocardiographic parameters) and heart/body weight ratio were not affected. Myocardial retention of [(11)C]HED, [(3)H]CGP12177, and (R)-[(11)C]rolipram were unchanged 1 week post-adriamycin. Compared to controls, 3 weeks post-treatment [(3)H]CGP12177 uptake decreased (left ventricle free wall and septum; P < 0.05), while [(11)C]HED and (R)-[(11)C]rolipram uptake were unaffected. Following acute increase in myocardial noradrenaline levels with desipramine treatment, (R)-[(11)C]rolipram retention increased in the left atrium, right ventricle, left ventricle free wall and septum (P < 0.05) in vehicle-, but not adriamycin-treated animals. CONCLUSION: Our results suggest that adriamycin-induced toxicity exhibits no change in presynaptic noradrenaline uptake, but decreased beta-adrenergic receptors in cardiac tissues, supporting a role for PET imaging of noradrenaline signaling in the study of anthracycline cardiotoxicity.
BACKGROUND: Altered sympathetic nervous system signaling is known to play a role in the cardiotoxicity of the anthracycline chemotherapeutic agents, but the interaction of pre- and postsynaptic function is not well understood. METHODS AND RESULTS: Our aim was to study the noradrenergic signaling in an established rat model of adriamycincardiotoxicity (15 mg/kg administered i.p. over 2 weeks) using radiotracers having potential applicability for imaging with positron emission tomography (PET). Ex vivo biodistribution was performed 1 and 3 weeks post-adriamycin treatment with the noradrenaline analogue [(11)C]meta-hydroxyephedrine ([(11)C]HED), beta-adrenergic receptor antagonist [(3)H]CGP12177, and phosphodiesterase-4 inhibitor (R)-[(11)C]rolipram. Cardiac function (echocardiographic parameters) and heart/body weight ratio were not affected. Myocardial retention of [(11)C]HED, [(3)H]CGP12177, and (R)-[(11)C]rolipram were unchanged 1 week post-adriamycin. Compared to controls, 3 weeks post-treatment [(3)H]CGP12177 uptake decreased (left ventricle free wall and septum; P < 0.05), while [(11)C]HED and (R)-[(11)C]rolipram uptake were unaffected. Following acute increase in myocardial noradrenaline levels with desipramine treatment, (R)-[(11)C]rolipram retention increased in the left atrium, right ventricle, left ventricle free wall and septum (P < 0.05) in vehicle-, but not adriamycin-treated animals. CONCLUSION: Our results suggest that adriamycin-induced toxicity exhibits no change in presynaptic noradrenaline uptake, but decreased beta-adrenergic receptors in cardiac tissues, supporting a role for PET imaging of noradrenaline signaling in the study of anthracyclinecardiotoxicity.
Authors: Miran Kenk; Michael Greene; James Thackeray; Robert A deKemp; Mireille Lortie; Stephanie Thorn; Rob S Beanlands; Jean N DaSilva Journal: Nucl Med Biol Date: 2006-11-16 Impact factor: 2.408
Authors: R S Beanlands; N A Shaikh; W H Wen; F Dawood; A M Ugnat; P R McLaughlin; R Carere; P P Liu Journal: J Mol Cell Cardiol Date: 1994-01 Impact factor: 5.000
Authors: M R Bristow; R Ginsburg; W Minobe; R S Cubicciotti; W S Sageman; K Lurie; M E Billingham; D C Harrison; E B Stinson Journal: N Engl J Med Date: 1982-07-22 Impact factor: 91.245
Authors: C D Manning; M M McLaughlin; G P Livi; L B Cieslinski; T J Torphy; M S Barnette Journal: J Pharmacol Exp Ther Date: 1996-02 Impact factor: 4.030
Authors: Maira S Oliveira; Marcos B Melo; Juliana L Carvalho; Isabela M Melo; Mario Sl Lavor; Dawidson A Gomes; Alfredo M de Goes; Marilia M Melo Journal: J Cancer Sci Ther Date: 2013
Authors: Carol Chen-Scarabelli; Chad McRee; Massoud A Leesar; Fadi G Hage; Tiziano M Scarabelli Journal: J Nucl Cardiol Date: 2016-05-25 Impact factor: 5.952